

CNMV
Markets Directorate General
C/ Edison núm. 4
28006 Madrid

Madrid, July 29, 2021

In accordance with article 227 of the recast Spanish Securities Market Act (*texto refundido de la Ley del Mercado de Valores*), approved by Royal Legislative Decree 4/2015, of 23 October, and related provisions, is hereby reported the following:

OTHER RELEVANT INFORMATION

The Board of Directors of Pharma Mar, S.A. (the “**Company**”), at its meeting held today, has agreed to:

- (i) To appoint Mr. Carlos Pazos Campos, independent Director, as President of the Appointments and Compensation and Sustainability Committee, of which he was already a member, for the same term of his position as Director of the Company, and in substitution of Ms. Ana Palacio Vallelersundi, who loses her status as independent Director in accordance with the provisions of the Capital Companies Act, upon the expiration yesterday, July 28, 2021, twelve years after her first appointment as Director.

Ms. Ana Palacio Vallelersundi continues as a member of the aforementioned Committee.

- (ii) To appoint Ms. Blanca Hernández Rodríguez, independent Director, as member of the Audit Committee for the same term of her position as Director of the Company.

Consequently, after the aforementioned appointments, the current composition of the Appointments and Compensation and Sustainability Committee and the Audit Committee is as follows:

Appointments and Compensation and Sustainability Committee

President: Mr. Carlos Pazos Campos
Member: Ms. Blanca Hernández Rodríguez
Member: Ms. Montserrat Andrade Detrell
Member: Ms. Ana Palacio Vallelersundi
Member and Secretary: Mr. Eduardo Serra Rexach

Audit Committee

President: Mr. Valentín de Torres-Solanot del Pino
Member: Ms. Ana Palacio Vallelersundi
Member: Mr. José Félix Pérez-Orive Carceller
Member: Mr. Carlos Solchaga Catalán
Member: Ms. Blanca Hernández Rodríguez
Non-member Secretary: Mr. Juan Gómez Pulido



Additionally, the Board of Directors of the Company has approved to modify: (i) section 2 of articles 13 and 14 of the Regulations of the Board of Directors in order to adapt the functions of the Audit Committee and the Appointments and Compensation and Sustainability Committee to the provisions of Law 5/2021, of April 12, amending the revised text of the Capital Companies Act, approved by Royal Legislative Decree 1/2010, of July 2, and other financial regulations, with respect to the promotion of long-term shareholder involvement in listed companies. In particular, the Audit Committee has been attributed the function of reporting on related-party transactions to be approved by the General Meeting or the Board of Directors; and (ii) Article 22.3 of the Regulations of the Board of Directors, so that following the content of recommendation number 25 of the Code of Good Governance of listed companies regarding the dedication of Directors, it is limited that Directors may not sit on more than four boards of directors of other listed companies other than the Company, with the qualifications set forth in said article.

The new revised text of the Regulations of the Board of Directors of the Company will be notified to the National Securities Market Commission through the procedure established for this purpose and is available on the Company's corporate website www.pharmamar.com. Likewise, it will be filed within the Commercial Registry of Madrid for its registration and the aforementioned amendments will be reported at the next General Shareholders' Meeting of the Company.